Clinical trial
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
NCT02374242 · Melanoma Institute Australia, Other · Active, not recruiting
Key facts
| NCT number | NCT02374242 |
|---|---|
| Title | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases |
| Official title | A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases |
| Acronym | ABC |
| Lead sponsor | Melanoma Institute Australia, Other |
| Collaborators | Melanoma and Skin Cancer Trials Limited Bristol-Myers Squibb Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Brain Metastases |
| Intervention type | Drug |
| Interventions | Nivolumab, Ipilimumab |
| Enrollment | 76 |
| Start date | Nov 4, 2014 |
| Primary completion | Sep 4, 2017 |
| Completion | Dec 1, 2028 |
| First posted | Feb 27, 2015 |
| Last update posted | Dec 10, 2025 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: